Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So, basically Amphastar won? MNTA can't do anything more at this point, right?
So, basically Amphastar won? MNTA can't do anything more at this point, right?
From TD Ameritrade:
MNTA shares bouncing off lows. Lovenox case loss in Appeals court will stand. I guess there goes the en banc hearing. Damn!
From TD Ameritrade:
MNTA shares bouncing off lows. Lovenox case loss in Appeals court will stand. I guess there goes the en banc hearing. Damn!
MNTA. What now? Why did it drop 50 cents to a new 52 week low.
Goldman Sachs downgrades CLF to a sell rating with a $25 target.
http://www.streetinsider.com/Analyst+PT+Change/Goldman+Sachs+Downgrades+Cliffs+Natural+Resources+(CLF)+to+Sell,+Sees+29%25+Downside/7893199.html
Can't fight Goldman. I will wait for $25 before initiating a position.
So, are you suggesting that EXEL's drug is going to get rejected on 11/29, since there has been no early approval? Thanks.
http://www.standard.co.uk/business/markets/market-roundup-all-that-glisters-is-not-gold-investec-analyst-tells-punters-8224638.html
Takeover rumours continued to circulate around the pharmaceutical industry ahead of results from AstraZeneca tomorrow. Chatter has it that since Astra — up 5.5p to 2905.75p — needs to restock its drug pipeline, it is taking a long look at US drug group Amarin. But it could have competition from GlaxoSmithKline and US-based Eli Lilly.
http://www.standard.co.uk/business/markets/market-roundup-all-that-glisters-is-not-gold-investec-analyst-tells-punters-8224638.html
Takeover rumours continued to circulate around the pharmaceutical industry ahead of results from AstraZeneca tomorrow. Chatter has it that since Astra — up 5.5p to 2905.75p — needs to restock its drug pipeline, it is taking a long look at US drug group Amarin. But it could have competition from GlaxoSmithKline and US-based Eli Lilly.
AstraZeneca may launch cash bid for Amarin, Daily Mail reports
According to the Daily Mail, AstraZeneca (AZN) may be planning to launch a cash bid for Amarin (AMRN). The Mail says other larger pharmaceutical companies, like Merck (MRK), Eli Lilly (LLY), Abbott (ABT) and Pfizer (PFE), "would love to get their hands" on Amarin for Vascepa.
http://www.theflyonthewall.com/permalinks/entry.php/AMRN;AZNid1629511/AMRN;AZN-Amarin-could-be-a-takeover-target-of--AstraZeneca-says-UBS
AstraZeneca may launch cash bid for Amarin, Daily Mail reports
According to the Daily Mail, AstraZeneca (AZN) may be planning to launch a cash bid for Amarin (AMRN). The Mail says other larger pharmaceutical companies, like Merck (MRK), Eli Lilly (LLY), Abbott (ABT) and Pfizer (PFE), "would love to get their hands" on Amarin for Vascepa.
http://www.theflyonthewall.com/permalinks/entry.php/AMRN;AZNid1629511/AMRN;AZN-Amarin-could-be-a-takeover-target-of--AstraZeneca-says-UBS
Adam Feurestein's brilliant calls
1. ARNA will get rejected
http://www.thestreet.com/story/11499658/1/arena-pharmas-own-data-point-to-weight-loss-drug-rejection.html
2. BPAX the next big thing in Biotech -- Libigel will be approved (odds are in its favor). He says its efficacy is not in doubt.
Adam Feurestein's brilliant calls
1. ARNA will get rejected
http://www.thestreet.com/story/11499658/1/arena-pharmas-own-data-point-to-weight-loss-drug-rejection.html
2. BPAX the next big thing in Biotech -- Libigel will be approved (odds are in its favor). He says its efficacy is not in doubt.
This is regarding AMRN's After Hours increase today.
Daily Mail is writing about AZN possibly buying AMRN
http://www.thisismoney.co.uk/money/markets/article-2221989/MARKET-REPORT-Amarin-cure-Astra.html
Daily Mail may have been the first to write about GSK possibly buying HGSI.
http://www.dailymail.co.uk/money/markets/article-2050257/MARKET-REPORT-GlaxoSmithKline-just-tonic.html
It did take 9-10 months before that buyout happened and at a much lower price.
This is regarding AMRN's After Hours increase today.
Daily Mail is writing about AZN possibly buying AMRN
http://www.thisismoney.co.uk/money/markets/article-2221989/MARKET-REPORT-Amarin-cure-Astra.html
Daily Mail may have been the first to write about GSK possibly buying HGSI.
http://www.dailymail.co.uk/money/markets/article-2050257/MARKET-REPORT-GlaxoSmithKline-just-tonic.html
It did take 9-10 months before that buyout happened and at a much lower price.
ZIOP reason for drop
http://www.forbes.com/sites/richardpearson/2012/10/18/110/
Is this a good explanation on why the FDA might grant NCE status for Vascepa?
In an article titled "Pharmaceutical Approval Update" published on the NIH site in September 2012, Dr. Marvin M. Goldenberg states the following:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3462608/
SRPT -- No insider sales after the almost 200% pop.
http://openinsider.com/search?q=SRPT
Some of these guys bought it under $3 (split adjusted). Hmm! Could they be expecting a much higher price?
No position, except for a couple of lottery Oct $34 / $35 calls and one Nov $40 call I am hoping that it doesn't end up being worthless
Adam gets no credit for that. The subtle changes were already discussed in a Seeking Alpha article that came out much before Adam's article.
http://seekingalpha.com/article/916081-amarin-nce-decision-delayed-again-what-the-8-k-really-tells-us?source=email_rt_article_readmore&ifp=0
Look at the comments on that to get an idea when that came out. The first comment is at 11:38 am.
Damn, I will take 68.26 or 58.26 or 48.26 or 38.26 or 28.26 or even 18.26 right now!
Come on Ritu set a target of 78.26 for MNTA! The enterprise value of all of MNTA's drugs are worth 78.26, don't you think?
mcbio,
You buying ASTX here? No Dacogen post approval bump in the price. Seems like a good time to accumulate.
Thanks.
This is the part that I don't understand. If they know something good might happen in the next couple of months and suspend sales, isn't that similar to insider trading? Yes, there is no buying / selling or trading, but isn't suspending sales on inside information still wrong? Thanks.
It is strange that Yahoo reports a close price of 3.08.
Nasdaq.com reports a close of 3.05
http://www.nasdaq.com/symbol/gkk/real-time
It doesn't report any after hours trades (but here it lists 3.08 as the close price)
http://www.nasdaq.com/symbol/gkk/after-hours
IHub lists a purchase of 84,421 shares at 4:03 pm at the 3.08 price.
http://ih.advfn.com/p.php?pid=trades&symbol=GKK
If you look at the trades executed from 3:59:30 to 4:00 (in the last 30 seconds of regular trading), there are a lot of purchases totaling more than 22,000 shares). IHub lists these as "Burst bas" type of trade.
Here's the definition of "Burst Basket"
http://www.investopedia.com/terms/b/burstbasket.asp#ixzz1Y9cKRLZj
Somebody certainly was buying a lot of shares in the last few minutes on Friday.
Hope this means good things going forward.
Make that seven weeks now. And the finish today. just as I had predicted
Sep 21st -- 3.05
http://www.nasdaq.com/symbol/gkk/real-time
Max Link exercises option for 35,000 shares at 2.72 and spends 95,200. Let us see more insider buying at around the $6 mark.
http://openinsider.com/search?q=clsn
y3maxx sent the CFO, CEO and others an e-mail urging them to stop these sales
More insider buys:
On Sep 14th, Jeffrey Wayne Church purchased 2,000 shares at 4.93.
http://openinsider.com/search?q=clsn
Institutional buying or insider buying? I don't see any insider buying listed here on this site.
http://openinsider.com/search?q=arry
However, I see this site lists the CLSN insider buying as recently as yesterday 9/14.
http://openinsider.com/search?q=clsn
Six straight weeks that GKK has closed higher
Aug 3rd -- 2.35
Aug 10th -- 2.39
Aug 17th -- 2.55
Aug 24th -- 2.62
Aug 31st -- 2.68
Sep 7th -- 2.77
Sep 14th -- 2.91
Where will we be on Sep 21st? (op ex)
Sep 21st -- 3.05??
http://www.finviz.com/futures.ashx
Look at the top row under Energy and you will see Natural Gas (NG) at 3.066. First time it crossed 3 yesterday in almost a month.
The OP was obviously referring to that as HEK got clobbered under the false perception that it was just a NG play
ASTX -- Director exercises option at 2.76 for 50,000 shares.
http://openinsider.com/search?q=astx
I am guessing that is good news for ASTX longs.
Just wondering if there will be a sell on the news of Dacogen European approval for AML, since there has been a steady rise from 2.40 or so on the hopes that this will be approved
AMARIN 12/702,889 patent allowed
Bibliographic Data
Application Number: 12/702,889 Customer Number: -
Filing or 371 (c) Date: 02-09-2010 Status: Allowed -- Notice of Allowance Not Yet Mailed
Application Type: Utility Status Date: 09-04-2012
Examiner Name: SZNAIDMAN, MARCOS L Location: ELECTRONIC
-
Another $106k insider buy on 8/27.
http://marketbrief.com/gkk/form4/insider-trading/2012/8/30/9714524?s=st
How long before the EMA review? Thanks